According to a new major clinical trial known as the ESSENCE trial, semaglutide—better known as Ozempic when used for Type 2 ...

WeightWatchers isn’t the only company to feel the disruptive power of the weight loss drugs. London-listed but Irish-based ...

The celebrated actress has lost more than 100Ib after turning to controversial diabetes jab Ozempic - now better known for its impact on tackling obesity ...

Novo Nordisk A/S (NYSE: NVO) is seeking FDA approval for the pill version of its obesity drug, Wegovy. The company highlights ...

Wegovy and Ozempic are both semaglutide weight loss medications, but they’re prescribed differently based on who qualifies.

Novo Nordisk's Q1 results show a dramatic expansion in sales beyond the US. Nevertheless, issues remain, and its outlook for ...

The FDA in February formally declared the end of the semaglutide shortage, which Novo Nordisk expects will help improve the ...

Eli Lilly won’t lose its grip on the weight loss market despite recent investor concerns. Meanwhile, Zocdoc releases an AI-powered scheduling assistant.

As Novo Nordisk works through a period of transition in the U.S. GLP-1 drug market, sales from the company's star obesity ...

Pedersen and Maggie Fick COPENHAGEN/LONDON (Reuters) -Drugmaker Novo Nordisk expects Wegovy weight-loss drug sales in the ...

WHEN Caitlin Cameron started taking fat jabs, she saw dramatic results – losing two stone in just three months. But for the ...

Novo Nordisk shares climbed more than 6% on Wednesday pre-market trading after the company reported solid first-quarter ...